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TECHNICAL NOTE /Cardiovascular
Multiple  bronchial  artery  aneurysms:
Successful  treatment  with  ethylene-vinyl
alcohol  copolymer  (Onyx®)
J.  Izaaryene ∗,  V.  Vidal,  J.-M.  Bartoli,  J.-Y.  Gaubert
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Bronchial  artery  aneurysm  (BAA)  in  an  uncommon  condition  that  has  serious  consequences
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due  to  possible  rupture  [1—3].  In  this  regard,  BAA  can  cause  life-threatening  hemor-
rhage  within  either  the  mediastinum  or  the  lungs  [1—3]. BAA  rupture  is  unpredictable
and  unrelated  to  the  BAA  diameter.  This  is  why  BAA  should  be  treated  once  the  diagnosis
is  made.  Conventional  treatment  consists  of  surgical  resection  but  transcatheter  arterial
embolization  using  a  variety  of  embolic  agents  has  demonstrated  efﬁcacy  [1—4].
We  report  multiple  BAAs  in  a  single  patient,  which  were  unsuitable  for  surgery  and
successfully  treated  using  Onyx® (ethylene  vinyl  alcohol  copolymer,  ev3-Endovascular  Inc.,
Plymouth,  MN,  USA).
Clinical case
A  59-year-old  woman  with  prior  history  of  uterine  carcinoma  was  referred  to  us  for  routine
follow-up.  She  was  in  complete  remission.  However,  the  patient  complained  of  intermit-
tent  dysphagia  and  dry  cough  that  appeared  one  year  before.  Multidetector  row  computed
tomography  (MDCT)  revealed  presence  of  BAA  that  developed  on  the  common  trunk  of  the
bronchial  artery  (Fig.  1) that  was  not  present  on  the  previous  MDCT  examinations.  BAA  was
located  immediately  after  the  arterial  ostium,  had  a  largest  axial  diameter  of  55-mm  with
parietal  calciﬁcation.  The  BAA  occupied  the  entire  mediastinum  under  the  aortic  arch,  and
was  responsible  for  mass  effect  on  the  esophagus,  the  trachea,  the  bronchi  and  the  right
branch  of  the  pulmonary  artery.  Careful  image  analysis  revealed  that  four  additional,  adja-
cent  small  BAAs  developed  from  the  left  and  right  efferent  arteries,  with  diameters  ranging
from  10-  to  25-mm  (Fig.  2).  During  multidisciplinary  meeting,  a  consensus  was  reached  to
treat  BAA  using  percutaneous  arterial  embolization.  The  procedure  was  performed  after
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Figure 1. MDCT of the thorax. a: MDCT image in the axial plane after intravenous administration of iodinated contrast material shows
b and the left bronchial artery (black arrow); b: MDCT image in the coronal
p rge feeding bronchial artery originating from aorta (arrowhead).
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Discussion
We  have  reported  multiple  BAAs  in  a  single  patient  involving
the  whole  bronchial  arterial  system  with  no  causing  factor.
Owing  to  the  presence  of  multiple  BAAs  located  on  the  com-
mon  arterial  trunk  and  distally  in  the  left  and  right  efferent
arteries,  surgery  was  not  recommended.  Technically  dur-
ing  embolization,  we  had  to  exclude  the  most  distal  BAAs
ﬁrst  to  avoid  the  risk  of  recanalization  and,  most  impor-
tantly  that  of  rupture.  In  addition,  we  used  a  liquid  agent
because  conventional  embolization  agents  such  as  metallic
coils,  microparticles,  plugs  and  stent-graft  would  not  have
allowed  safely  excluding  the  most  distal  BAA  and  might  have
carried  the  risk  of  recanalization  by  collateral  circulation
from  systemic  non  bronchial  arteries.  In  this  context,  Onyx®
was  the  embolic  agent  of  choice  to  overcome  the  problems
of  endovascular  navigation  and  to  ﬁrst  obtain  a  distal  occlu-
sion,  and  then  a  proximal  occlusion.ronchial artery aneurysm (arrow), the efferent artery (arrowhead) 
lane shows relationships between the aneurysm (arrow) and the la
ocal  anesthesia  through  a  right  femoral  artery  access.  After
elective  catheterization  of  the  distal  bronchial  artery  with
 5-Fr  catheter,  dominant  BAA  and  satellite  BAAs  were
mbolized  using  a  coaxial  microcatheter  (Echelon  10TM,
v3-Endovascular  Inc.)  in  a  retrograde  fashion,  from  the
ost  distal  BAA  to  the  most  proximal  one,  in  order  to
each  the  largest  and  most  proximal  one  at  the  end  of
he  procedure.  Embolization  was  primarily  performed  with
nyx® 18  (6%  EVOH)  (Fig.  3).  A  ‘‘buffer’’  injection  tech-
ique  was  used,  which  is  speciﬁc  to  Onyx® and  allows  a
ore  secure  embolization.  In  order  to  prevent  reﬂux  into
he  aorta,  multiple  ﬁbered  interlocking  detachable  metallic
oils  (Interlock-35,  Boston  Scientiﬁc,  Watertwon,  MA,  USA)
ere  used  to  embolize  the  arterial  ostium.  Control  thoracic
ortography  showed  no  persistent  opaciﬁcation  of  BAAs.  The
atient  was  discharged  24  hours  later  in  the  absence  of  any
linical  symptom.  Genetical  investigations  did  not  reveal
ny  predisposing  abnormalities  that  might  have  favored  the
ccurrence  of  BAAs.  Repeat  control  MDCT  one  month,  one
ear  and  two  years  later  showed  complete  absence  of  BAA
paciﬁcation  and  no  recurring  clinical  symptoms.
igure 2. Three-dimensional volume rendered image on inferior
iew shows multiple additional small bronchial artery aneurysms
arrows).
BAA  can  be  intrapulmonary,  mediastinal  or  both  [1—5].
Mediastinal  BAAs  are  very  rare.  They  are  observed  on
Figure 3. Per-procedure angiogram shows main aneurysm
embolization with coils and Onyx®.
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less  than  1%  of  all  selective  bronchial  arteriograms.  Many
predisposing  conditions  have  been  described  in  the  phys-
iopathology  of  BAAs,  including  bronchiectasis,  atheroscle-
rosis,  trauma,  radiation  therapy,  chronic  infection,  and
Osler—Weber—Rendu  syndrome  [5].  In  a  substantial  number
of  cases,  no  etiologies  or  favoring  factors  can  be  identiﬁed.
BAA  may  be  incidentally  detected  on  chest  MDCT.  How-
ever,  large  mediastinal  BAA  can  present  with  superior  vena
cava  syndrome  [4],  hematemesis  from  esophageal  erosion  or
acute  rupture  [1—4].  BAA  is  potentially  life  threatening  and
its  rupture  is  unpredictable  and  unrelated  to  the  aneurys-
mal  diameter.  This  is  why  they  should  be  treated  once  the
diagnosis  is  conﬁrmed.
Until  the  last  decade,  BAA  had  been  treated  mainly  by
surgery,  with  resection  or  ligation  of  the  aneurysm  through
thoracotomy.  However,  this  procedure  conveys  high  morbid-
ity  and  mortality  rates.  Currently,  the  treatment  of  BAA
depends  on  its  location.  For  BAA  located  within  the  lung
parenchyma,  percutaneous  arterial  embolization  is  the  pre-
ferred  option.
Onyx® is  mainly  used  by  interventional  neuroradiologists
for  the  treatment  of  cerebral  aneurysms  [6].  A  combina-
tion  of  stent  placement  and  Onyx® at  a  concentration  of
20%  of  ethylene  vinyl  alcohol  has  been  successfully  used  for
the  endovascular  treatment  of  giant  and  large  intracranial
aneurysms  [6]  with  persistent  aneurysm  occlusion  on  late
control  angiograms  and  clinical  follow-up.  However,  a  limi-
tation  to  the  use  of  Onyx® for  peripheral  artery  embolization
is  its  relatively  high  cost  by  comparison  with  other  embolic
agents  such  as  N-butyl-2-cyanoacrylate.
In  conclusion,  we  have  reported  the  ﬁrst  use  of  Onyx®
for  the  endovascular  management  of  BAA  with  encouraging127
esults.  Further  experience  is  however  needed  to  conﬁrm  its
fﬁcacy  in  this  speciﬁc  indication.
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